Immunovant, Inc.IMVT

Immunovant, Inc. Segments Disclosure

10-KFiled May 29, 20252 min read
Segment Information
The Company operates in a single operating segment and has one reportable segment, which includes all activities related to the discovery, development and manufacturing of its product candidates. The determination of a single segment is consistent with the consolidated financial information regularly provided to the Company’s chief operating decision maker (“CODM”). The Company’s CODM is its chief executive officer. The CODM, in alignment with the Company’s strategic goals, uses consolidated net loss to monitor budget to actual results and cash forecast models for assessing performance and making operating decisions. The measurement of segment assets is reported on the consolidated balance sheet as total assets.

The Company’s significant segment expenses are as follows (in thousands):

Years Ended March 31,
202520242023
Therapeutic area-specific research and development:
Endocrine diseases$63,073 $33,205 $26,377 
Neurological diseases93,224 41,060 52,100 
Rheumatology diseases23,897 — — 
Dermatology diseases15,633 — — 
Other clinical and nonclinical9,327 39,811 5,553 
Other unallocated research and development44,264 24,562 26,460 
Personnel-related research and development (1)
111,499 74,290  49,767 
Acquired in-process research and development— 12,500 10,000 
Personnel-related general and administrative (2)
41,095 34,684  27,910 
Other general and administrative (3)
36,140 22,597 20,109 
Interest income(24,732)(24,948)(7,578)
Other segment items (4)
420 1,575 262 
Net loss$413,840 $259,336 $210,960 
___________
(1)Includes stock-based compensation expense of $27,014, $20,409 and $14,805 for the years ended March 31, 2025, 2024 and 2023, respectively
(2)Includes stock-based compensation expense of $22,473, $20,707 and $17,491 for the years ended March 31, 2025, 2024 and 2023, respectively
(3)Other general and administrative expenses primarily include legal and other professional fees, information technology costs and market research costs
(4)Other segment items include other expense (income), net and provision (benefit) for income taxes
Free Sentinel

Want the next Immunovant, Inc. segments disclosure the moment it drops?

Set a Sentinel and we'll alert you the moment Immunovant, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.

Track for free

About Segments Disclosures

Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.

Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.

Other Available Disclosures

Income TaxesCommitmentsStock CompensationNew Standards